New PET tracer could predict CAR-T success in lymphoma patients
NCT ID NCT06522932
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 26 times
Summary
This early-phase study tests a new PET imaging tracer called 64Cu-GRIP B in 32 adults with relapsed or hard-to-treat non-Hodgkin lymphoma who are receiving CAR-T therapy. The tracer aims to detect a protein released by active immune cells, which may help identify tumors that will respond well to treatment. The goal is to see if this imaging method can predict treatment success, not to directly treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.